Association of perineural invasion with outcomes after neodjuvant chemoradiation for locally advanced rectal adenocarcinoma.

Authors

null

Priyanka Vinod Chablani

The Ohio State University College of Medicine, Columbus, OH

Priyanka Vinod Chablani , Phuong Nguyen , Charles Andrew Robinson , Xueliang Jeff Pan , Steve Andrew Walston , Evan John Wuthrick , Terence Marques Williams

Organizations

The Ohio State University College of Medicine, Columbus, OH, Department of Radiation Oncology, The Ohio State University, Columbus, OH, Center for Biostatistics, The Ohio State University Comprehensive Cancer Center – The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, The Ohio State University, Columbus, OH

Research Funding

No funding sources reported

Background: Perineural invasion (PNI) as a prognostic indicator has not been well studied in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiation (nCRT). In this study, we investigated the incidence and prognostic significance of PNI in patients with stages II-III locally advanced rectal cancer treated with nCRT. Methods: We performed a retrospective study of 110 consecutive patients treated with nCRT for locally advanced rectal adenocarcinoma at a single institution from 2004 to 2011. 88 of these patients had residual tumor in the resected specimen after nCRT. We evaluated the association of PNI with clinical outcomes, including disease-free survival (DFS), distant-metastasis-free survival (DMFS), and overall survival (OS), using log-rank and Cox proportional hazard modeling. Results: Of the 88 patients with residual tumor at surgery, 14 patients (16%) had PNI and 74 patients (84%) did not. Baseline distribution of selected variables in the PNI+ and PNI- groups are shown in Table 1. Median follow-up was 27 months (range 0.9 to 84 months). The median DFS was 13.5 months for PNI+ patients and 39.8 months for PNI- patients (p<0.0001). The median DMFS was 13.5 months for PNI+ patients and median not reached (> 40 months) for PNI- patients (p<0.0001). We did not detect a significant association between the presence of PNI and worse OS, perhaps due to a high rate of censored patients in the OS analysis. In a multivariate model including pT stage, pN stage, tumor location, tumor size, type of surgery, and radial margin status, PNI remained a significant predictor of DFS (HR 16.8, 95% CI, 3.7–75.5, p<0.0002) and DMFS (HR 18.9, 95% CI, 4.4–81.9, p<0.0001). Conclusions: For patients with locally advanced rectal cancer treated with nCRT prior to surgical resection, PNI found at the time of surgery is significantly associated with worse DFS and DMFS.

Selected baseline characteristics between PNI+ and PNI- groups. Median age – 59 (range 22-84 years); 40% women, 60% men.

CharacteristicPNI-positive
n=14
PNI-negative
n=74
p
pT stage0.017
1-22 (14%)36 (49%)
3-412 (86%)38 (51%)
pN stage0.054
N04 (29%)42 (57%)
N+10 (71%)32 (43%)
Surgery type
LAR5 (38%)42 (64%)0.091
APR8 (62%)24 (36%)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 750)

DOI

10.1200/jco.2015.33.3_suppl.750

Abstract #

750

Poster Bd #

E40

Abstract Disclosures

Similar Abstracts

First Author: Valentina Burgio

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Surgical decision making in locally advanced esophageal adenocarcinoma.

First Author: Van Christian Sanderfer